Matt Bryant

Matt has been a visionary and driving force around transforming the patient experience in clinical trials throughout his two decades in the biopharmaceutical industry. His formal background in Computer Science and Business has supported his personal passion to evolve the clinical trial model by delivering numerous products and applications serving patients, participants, caregivers, investigators, startups, and established enterprises. In addition to holding a variety of roles in commercial, clinical development, innovation, technology and design at Eli Lilly, Amgen and currently, Gilead Sciences, Matt has also created new ventures such as being a founding member of the direct-to-patient startup, Lightship, backed by Khosla Ventures, McKesson Ventures, Define Ventures, Brook Byers, and Marc Benioff.Matt has lived and worked in the largest pharmaceutical markets around the world including the US, Japan, China, and EU. He has spent extensive time with patients, caregivers, investigators, and regulatory agencies to listen and act on the necessary infrastructure to evolve how clinical programs are designed and delivered.